Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
17.18
-0.22 (-1.26%)
Dec 20, 2024, 4:00 PM EST - Market closed
Travere Therapeutics Stock Forecast
Stock Price Forecast
The 13 analysts with 12-month price forecasts for TVTX stock have an average target of 23.46, with a low estimate of 10 and a high estimate of 41. The average target predicts an increase of 36.55% from the current stock price of 17.18.
Analyst Consensus: Buy
* Price targets were last updated on Nov 14, 2024.
Analyst Ratings
The average analyst rating for TVTX stock from 13 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 4 | 4 | 4 |
| Buy | 5 | 4 | 3 | 6 | 6 | 6 |
| Hold | 5 | 6 | 4 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 12 | 13 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Hold Maintains $12 → $22 | Hold | Maintains | $12 → $22 | +28.06% | Nov 14, 2024 |
| Scotiabank | Scotiabank | Buy Maintains $23 → $27 | Buy | Maintains | $23 → $27 | +57.16% | Nov 1, 2024 |
| Barclays | Barclays | Buy Maintains $18 → $20 | Buy | Maintains | $18 → $20 | +16.41% | Nov 1, 2024 |
| Wells Fargo | Wells Fargo | Hold → Buy Upgrades $9 → $27 | Hold → Buy | Upgrades | $9 → $27 | +57.16% | Oct 21, 2024 |
| Scotiabank | Scotiabank | Buy Initiates $23 | Buy | Initiates | $23 | +33.88% | Oct 16, 2024 |
Financial Forecast
Revenue This Year
235.53M
from 145.24M
Increased by 62.17%
Revenue Next Year
368.33M
from 235.53M
Increased by 56.38%
EPS This Year
-3.83
from -1.50
EPS Next Year
-1.28
from -3.83
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 253.5M | 567.3M | 756.9M | |||
| Avg | 235.5M | 368.3M | 532.4M | |||
| Low | 217.6M | 263.8M | 364.6M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 74.5% | 140.8% | 105.5% | |||
| Avg | 62.2% | 56.4% | 44.5% | |||
| Low | 49.8% | 12.0% | -1.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -2.54 | 0.91 | 2.68 | |||
| Avg | -3.83 | -1.28 | 0.67 | |||
| Low | -4.02 | -2.24 | -0.54 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.